Works matching AU Kimmeskamp-Kirschbaum, Nina
Results: 10
Safety and tolerability of the M2 muscarinic acetylcholine receptor modulator BAY 2413555 in heart failure with reduced ejection fraction in the REMOTE-HF study.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-77111-4
- By:
- Publication type:
- Article
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy.
- Published in:
- JAMA: Journal of the American Medical Association, 2015, v. 314, n. 9, p. 884, doi. 10.1001/jama.2015.10081
- By:
- Publication type:
- Article
Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy.
- Published in:
- American Journal of Nephrology, 2015, v. 40, n. 6, p. 572, doi. 10.1159/000371497
- By:
- Publication type:
- Article
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies.
- Published in:
- Fundamental & Clinical Pharmacology, 2016, v. 30, n. 2, p. 172, doi. 10.1111/fcp.12170
- By:
- Publication type:
- Article
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 488, doi. 10.1002/cpdd.263
- By:
- Publication type:
- Article
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
- Published in:
- European Heart Journal, 2016, v. 37, n. 27, p. 2105, doi. 10.1093/eurheartj/ehw132
- By:
- Publication type:
- Article
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
- Published in:
- European Journal of Heart Failure, 2015, v. 17, n. 2, p. 224, doi. 10.1002/ejhf.218
- By:
- Publication type:
- Article